kabutan

KYORIN Pharma, Ordinary Profit Unexpectedly Turn to Loss for Last Fiscal Year, 43% Decrease in The Current Fiscal Year, Dividend to Cut by 32 Yen

Tue May 12, 2026 3:30 pm JST Earnings

4569 KYORIN Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

KYORIN Pharmaceutical Co.,Ltd. <4569> [TSE Prime] announced its financial results after the market closed on May 12th (15:30). The consolidated ordinary profit for the fiscal year ended March 2026 decreased by 69.5% from the previous period to 4.03 billion yen, falling below the forecast of 6.30 billion yen. For the fiscal year ending March 2027, the consolidated ordinary profit is expected to drop by 42.9% from the previous period to 2.30 billion yen.

At the same time, the company has decided to significantly reduce the dividend this fiscal year to 25 yen, a decrease of 32 yen from the previous fiscal year.

In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit/loss turned to a loss of 1.06 billion yen (compared to a profit of 9.46 billion yen in the same period last year). The operating profit/loss margin drastically worsened from 23.2% in the same period last year to -3.1%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 119,532 6,234 6,822 5,475 95.4 52 May 10, 2024 J-GAAP
Mar, 2025 130,087 12,567 13,219 9,086 158.2 57 May 12, 2025 J-GAAP
Mar, 2026 126,257 3,567 4,031 3,448 60.0 57 May 12, 2026 J-GAAP
YoY -2.9% -71.6% -69.5% -62.1% -62.0%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Guidance 127,000 6,100 6,300 4,800 83.6 57 May 12, 2025 J-GAAP
Mar, 2026 Results 126,257 3,567 4,031 3,448 60.0 57 May 12, 2026 J-GAAP
Revision Rate -0.6% -41.5% -36.0% -28.2% -28.2%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 58,731 1,363 1,582 1,494 26.0 20 Nov 7, 2025 J-GAAP
Apr - Sep, 2026 Guidance 57,800 -300 -100 0 0.0 10 May 12, 2026 J-GAAP
YoY -1.6% － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 130,087 12,567 13,219 9,086 158.2 57 May 12, 2025 J-GAAP
Mar, 2026 126,257 3,567 4,031 3,448 60.0 57 May 12, 2026 J-GAAP
Mar, 2027 Guidance 121,800 2,000 2,300 1,500 26.1 25 May 12, 2026 J-GAAP
YoY -3.5% -43.9% -42.9% -56.5% -56.5%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2025 40,801 9,452 9,466 6,647 115.7 23.2 May 12, 2025 J-GAAP
Apr - Jun, 2025 30,229 2,368 2,624 2,100 36.6 7.8 Jul 31, 2025 J-GAAP
Jul - Sep, 2025 28,502 -1,005 -1,042 -606 -10.6 -3.5 Nov 7, 2025 J-GAAP
Oct - Dec, 2025 33,725 3,246 3,515 2,625 45.7 9.6 Feb 4, 2026 J-GAAP
Jan - Mar, 2026 33,801 -1,042 -1,066 -671 -11.7 -3.1 May 12, 2026 J-GAAP
YoY -17.2% － － － －

Related Articles